M. C. Khosla

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide.

Marc Schiavone, Robson A.S. Santos, K. Bridget Brosnihan et al. · Proceedings of the National Academy of Sciences · 1988 · 286 citations · Full text

Social Sciences, Gastrointestinal Peptide Hormone, Neuroendocrine Mechanism +16

Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats

Maria José Campagnole‐Santos, Debra I. Diz, Robson A.S. Santos et al. · American Journal of Physiology-Heart and Circulatory Physiology · 1989 · 170 citations

Differential baroreceptor reflex modulation by centrally infused angiotensin peptides

Maria José Campagnole‐Santos, S. B. Heringer, Evandro Batista et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 1992 · 155 citations

Hypertension, Ang Iii, Ang Ii +19